DiaMedica Therapeutics Inc. announced the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs. Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group Inc. where she has oversight for development of an integrated clinical, regulatory and CMC strategy for the successful registration of the company's compounds.

Ms. Lewis joined the executive management team at Replimune in May 2021 after serving on Replimune's board of directors since November 2020.Prior to her officer position with Replimune, Tanya was Executive Vice President, Chief Regulatory Strategy andStrategic Operations at Karyopharm Therapeutics Inc., a publicly traded biopharmaceutical company, where she navigated the approval of XPOVIO®. Prior to joining Karyopharm, Ms. Lewis held leadership positions at several companies, including Tesaro and Millennium Pharmaceuticals, where she developed approval strategies and led interactions with U.S. and European regulators for registration trial designs and approvals. Ms. Lewis started her career at Genzyme Corporation in regulatory affairs.

Ms. Lewis's past accomplishments include the successful negotiations for registration trial designs, approval, and/or commercialization of VELCADE, VARUBI, INTEGRILIN and ZEJULA.